Tirzepatide vs MOTS-c
Side-by-Side Comparison
| Attribute | Tirzepatide | Mots C |
|---|---|---|
| Category | Metabolic / Dual GIP-GLP-1 Agonist | Metabolic / Mitochondrial |
| Mechanism | Tirzepatide (MW ~4813 g/mol, C225H348N48O68) simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. | MOTS-c activates AMPK by inhibiting the folate cycle, causing accumulation of AICAR (an AMP analog). Activated AMPK shifts cells into energy-efficient mode: enhancing glucose uptake, fatty-acid... |
| Evidence Rating | A — FDA Approved | D — Preclinical |
| Clinical Status | FDA-approved (Mounjaro for T2D, Zepbound for obesity and OSA) | Research-only / No human clinical trials completed (Phase 1 of analog CB4211 only) |
| Safety Profile | Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting; Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems | No adverse effects reported in preclinical animal studies; Human tolerability is completely unknown for native MOTS-c (no completed human trials) |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 2.5–15 mg/week, titrated every 4 weeks | 5–10 mg SC per injection |
| Frequency | Once weekly | Once daily or 3–5x weekly |
| Molecular Weight | ~4813.5 g/mol | ~2174.6 g/mol |
| Half-Life | ~5 days (116 hours) | Several hours; tissue effects may persist longer |
Overview
Tirzepatide and MOTS-c are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Tirzepatide — Mechanism & Evidence
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) including severe obstructive sleep apnea in adults with obesity. It is a 39-amino-acid peptide with a C20 fatty di-acid moiety that promotes albumin binding, enabling once-weekly dosing. Clinical trials consistently demonstrate it delivers the most substantial weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks.
Key claims: Superior weight loss compared to semaglutide; Improves blood sugar control; May improve liver fat / NASH.
MOTS-c — Mechanism & Evidence
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed.
Key claims: Improves insulin sensitivity and glucose metabolism; Exercise mimetic effects; Anti-obesity effects.
Shared Research Applications
Both peptides are studied for: Metabolic Health.
Tirzepatide is also researched for: Weight Management.
MOTS-c is also researched for: Anti-Aging.
Safety Considerations
Tirzepatide: Common (5%+ in trials): abdominal pain, burping, constipation, diarrhea, dyspepsia, fatigue, GERD, hair loss, hypersensitivity reactions, injection site reactions, nausea, vomiting Serious but rare: pancreatitis, gallbladder events, dehydration leading to kidney problems FDA boxed warning for thyroid C-cell tumors (rodent data); call doctor for neck lump, swallowing difficulty, hoarseness, or shortness of breath
MOTS-c: No adverse effects reported in preclinical animal studies Human tolerability is completely unknown for native MOTS-c (no completed human trials) Modified analog CB4211 showed good tolerability in Phase 1
Related Products
Tirzepatide 10mg
10mg
MOTS-C 20mg
20mg
Related Research News
Is Tirzepatide Better Than Semaglutide for Weight Loss? Comparison
A comparison examines if Tirzepatide outperforms Semaglutide for weight loss. The two drugs are directly contrasted on this measure. This regulatory news covers the key question of superiority.
Daily Orforglipron Preserves Weight Loss After Semaglutide or Tirzepatide
Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide. The medication supports maintenance of weight reduced during prior use of these treatments. Its once-a-day schedule aids in sustaining results from semaglutide or tirzepatide therapy.
FDA Proposes Ban on Bulk Compounding of Semaglutide and Tirzepatide
The U.S. Food and Drug Administration has proposed a ban on bulk compounding of semaglutide and tirzepatide. This regulatory proposal names semaglutide and tirzepatide as the drugs subject to the ban. The action focuses on prohibiting bulk compounding for these two medications.